Ipca Laboratories reported 12% domestic revenue growth in Q1FY25, with higher EBITDA margin. The company reduced FY25 revenue growth guidance to ~9% and raised EBITDA margin guidance to 18.5–19.0%.
What is covered in the Full Insight:
Introduction
Financial Performance
Challenges and Setbacks
Strategic Initiatives and Innovations
Share Performance and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.